- 1 January 2010
- journal article
- Published by Springer Nature in Drugs
- Vol. 70 (1) , 41-56
Abstract
Nebivolol is a third-generation β-adrenergic receptor antagonist (β-blocker) with high selectivity for β1-adrenergic receptors. In addition, it causes vasodilatation via interaction with the endothelial L-arginine/nitric oxide (NO) pathway. This dual mechanism of action underlies many of the haemodynamic properties of nebivolol, which include reductions in heart rate and blood pressure (BP), and improvements in systolic and diastolic function. With respect to BP lowering, the NO-mediated effects cause a reduction in peripheral vascular resistance and an increase in stroke volume with preservation of cardiac output. Flow-mediated dilatation and coronary flow reserve are also increased during nebivolol administration. Other haemodynamic effects include beneficial effects on pulmonary artery pressure, pulmonary wedge pressure, exercise capacity and left ventricular ejection fraction. In addition, nebivolol does not appear to have adverse effects on lipid metabolism and insulin sensitivity like traditional β-blockers. The documented beneficial haemodynamic effects of nebivolol are translated into improved clinical outcomes in patients with hypertension or heart failure. In patients with hypertension, the incidence of bradycardia with nebivolol is often lower than that with other currently available β-blockers. This, along with peripheral vasodilatation and NO-induced benefits such as antioxidant activity and reversal of endothelial dysfunction, should facilitate better protection from cardiovascular events. In addition, nebivolol has shown an improved tolerability profile, particularly with respect to events commonly associated with β-blockers, such as fatigue and sexual dysfunction. Data from SENIORS (Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure) showed that significantly fewer nebivolol versus placebo recipients experienced the primary endpoint of all-cause mortality or cardiovascular hospitalization. The benefits of nebivolol therapy were shown to be cost effective. Thus, nebivolol is an effective and well tolerated agent with benefits over and above those of traditional β-blockade because of its effects on NO release, which give it unique haemodynamic effects, cardioprotective activity and a good tolerability profile.Keywords
This publication has 91 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Nebivolol: A Highly Selective β1‐Adrenergic Receptor Blocker That Causes Vasodilation by Increasing Nitric OxideCardiovascular Therapeutics, 2008
- β-Blockers and Coronary Flow ReserveDrugs, 2008
- Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trialAmerican Heart Journal, 2007
- Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosumLife Sciences, 2007
- Metabolic Profile of Nebivolol, a ??-Adrenoceptor Antagonist with Unique CharacteristicsDrugs, 2007
- Different effects of atenolol and nebivolol on coronary flow reserveHeart, 2006
- Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathyHeart, 2006
- NebivololDrugs, 2006
- Comparison of the Subacute Hemodynamic Effects of Atenolol, Propranolol, Pindolol, and NebivololAngiology, 1990